Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.71 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.71 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.71 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 12/20 | 0.69 |
| ▸ | CA2 | P00918 | 12/20 | 0.69 |
| ▸ | CA9 | Q16790 | 8/20 | 0.69 |
| ▸ | CA12 | O43570 | 6/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | FGB | P02675 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | PLEC | Q15149 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3220192 | 0.87 | GAA (0.71) | KMT2AMEN1POLBPSMD14MAPT | |
| SCHEMBL10248292 | 0.86 | KMT2A (0.60) | KMT2AMEN1POLBPSMD14MAPT | |
| SCHEMBL8422583 | 0.82 | CA2 (1.00) | KMT2AMEN1POLBPSMD14MAPT | |
| SCHEMBL15899964 | 0.82 | KMT2A (0.54) | KMT2AMEN1POLBPSMD14MAPT | |
| SCHEMBL4636418 | 0.81 | HPGDS (0.73) | KMT2AMEN1POLBCA1CA2 | |
| SCHEMBL4669569 | 0.79 | KMT2A (0.74) | KMT2AMEN1RECQLCA1CA2 | |
| SCHEMBL4636456 | 0.76 | NPC1 (0.65) | POLBMAPTRECQLCYP2C9ALDH1A1 | |
| SCHEMBL4636076 | 0.76 | HTT (0.68) | KMT2AMEN1POLBALDH1A1L3MBTL1 | |
| SCHEMBL4671454 | 0.75 | CA1 (0.55) | KMT2AMEN1POLBPSMD14MAPT | |
| SCHEMBL8804735 | 0.75 | L3MBTL1 (0.77) | KMT2AMEN1POLBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | KMT2A 3407/4885MEN1 4523/4885POLB 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.